Reference number : 236-2017-2018-Q4-00868, amendment number : , agreement type : G, recipient legal name : Mason, Andrew L, recipient country : CA, recipient province : AB, recipient city : Edmonton, recipient postal code : T6G 2E1, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 703800.0, agreement start date : 2018-04-01, agreement end date : 2022-03-31, description english : Pilot study of emtricitabine, tenofovir alafenamide and raltegravir for patients with primary biliary cholangitis, description french : Pilot study of emtricitabine, tenofovir alafenamide and raltegravir for patients with primary biliary cholangitis, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2018-19 to 2021-22), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2018-19 à 2021-22), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada